KPV Evidence Guide
Evidence for KPV is too preliminary to support a research protocol with confidence. All data comes from rodent colitis models and in vitro work, with no human pharmacokinetic data, no clinical trials, and no independent replication in humans. Of the Immune Support and gut-focused compounds in this library, compounds with actual clinical data (such as larazotide for tight junction modulation) are better-evidenced starting points.
Our Take
Evidence for KPV is too preliminary to support a research protocol with confidence. All data comes from rodent colitis models and in vitro work, with no human pharmacokinetic data, no clinical trials, and no independent replication in humans. Of the Immune Support and gut-focused compounds in this library, compounds with actual clinical data (such as larazotide for tight junction modulation) are better-evidenced starting points.
- Evidence context
- NF-kB pathway anti-inflammatory mechanistic research, gut mucosal protection models (preclinical only)
- Evidence grade
- Level D
- Confidence
- Low
- Reference context
- Reported research reference: No established human protocol
Benefits and Evidence
- Gut Inflammation Reduction: Level D, mostly non-human evidence - Animal models of colitis show significant reduction in intestinal inflammation, mucosal damage scores, and inflammatory cytokine levels when KPV is administered orally or via nanoparticles.
- Systemic Anti-Inflammatory: Level D, mostly non-human evidence - Preclinical studies demonstrate broad anti-inflammatory effects in multiple tissue types, including skin and joints, through NF-kB pathway suppression.
- Wound Healing Support: Level D, mostly non-human evidence - Limited in vitro and animal data suggest KPV may accelerate epithelial wound closure by reducing inflammatory signaling at wound sites.
Side Effects and Warnings
- Very limited safety data in humans
- No significant adverse effects reported in animal studies
- Possible mild GI discomfort with oral dosing
- Not FDA-approved for any indication
- All evidence is preclinical
- No established human safety profile
- Quality and purity of commercial sources may vary
Research Dosage References
- <strong>Oral (capsule)</strong> - 200-500 mcg - Once or twice daily - Oral dosing targets GI tract inflammation directly. Absorbed via PepT1 transporter in the intestinal epithelium.
- <strong>Subcutaneous injection</strong> - 200-500 mcg - Once daily - Used for systemic anti-inflammatory effects. No established clinical dosing protocols.
- <strong>Topical</strong> - 100-200 mcg - Once or twice daily - Applied to skin for localized anti-inflammatory effects. Experimental use only.
Mechanism of Action
KPV exerts anti-inflammatory effects through several mechanisms: 1. NF-kB inhibition: Directly enters cells and inhibits NF-kB activation, reducing transcription of pro-inflammatory genes. 2. Inflammatory cytokine suppression: Downregulates TNF-alpha, IL-6, and IL-1beta production in immune cells and epithelial cells. 3. PepT1 transporter uptake: Actively transported into colonocytes via PepT1, enabling direct anti-inflammatory action in the gut mucosa. 4. Inflammasome modulation: Reduces NLRP3 inflammasome activation in macrophages and intestinal epithelial cells.
Legal Status
KPV is not FDA-approved and is available as a research peptide in most jurisdictions. It is not a controlled substance. No WADA listing exists for this peptide specifically.
Primary Sources
- KPV nanoparticles reduce intestinal inflammation in murine colitis models. J Clin Invest, 2008.
- Alpha-MSH C-terminal tripeptide KPV inhibits NF-kB in intestinal epithelial cells. PLoS One, 2012.
Quick Answers
Where is the strongest evidence for KPV?
Evidence for KPV is too preliminary to support a research protocol with confidence. All data comes from rodent colitis models and in vitro work, with no human pharmacokinetic data, no clinical trials, and no independent replication in humans. Of the Immune Support and gut-focused compounds in this library, compounds with actual clinical data (such as larazotide for tight junction modulation) are better-evidenced starting points. Evidence context: NF-kB pathway anti-inflammatory mechanistic research, gut mucosal protection models (preclinical only).
What are the main side effects of KPV?
KPV side effects and warning signals include Very limited safety data in humans, No significant adverse effects reported in animal studies, Possible mild GI discomfort with oral dosing, Not FDA-approved for any indication, and All evidence is preclinical.
What evidence level is KPV?
KPV is rated Level D; the listed research status is Preclinical.